Status:
COMPLETED
A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Hepatitis C, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This 2 part study will evaluate the efficacy and safety of 12 and 24 weeks treatment with RO5190591 (danoprevir) in combination with Pegasys and Copegus, compared to Pegasys and Copegus alone, in trea...
Eligibility Criteria
Inclusion
- adult patients, \>=18 years of age;
- chronic hepatitis C, genotype 1;
- treatment-naive.
Exclusion
- liver cirrhosis and other forms of liver disease;
- HIV infection;
- hepatocellular cancer;
- cardiac disease.
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
229 Patients enrolled
Trial Details
Trial ID
NCT00963885
Start Date
August 1 2009
End Date
January 1 2012
Last Update
November 2 2016
Active Locations (43)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States, 85054
2
Long Beach, California, United States, 90822
3
Los Angeles, California, United States, 90045
4
Sacramento, California, United States, 95817